Warner L, Skorecki K, Blendis L M, Epstein M
Nephrology Section, Veterans Affairs Medical Center, Miami, Florida 33125.
Hepatology. 1993 Mar;17(3):500-13.
A working formulation for the role of ANF in the sodium retention of cirrhosis is summarized in Figure 4. Sodium retention is initiated early in cirrhosis, either as a result of hepatic venous outflow block or of primary vasodilation. The consequent intravascular volume expansion causes increases in ANF levels. At this stage of disease, the rise in ANF level is sufficient to counterbalance the antinatriuretic influences. However, this occurs at the expense of an expanded intravascular volume with the potential for overflow ascites. With progression of disease, disruption of intrasinusoidal Starling forces and loss of volume from the vascular compartment into the peritoneal compartment occur. This underfilling of the circulation may attenuate further increases in plasma ANF and promotes the activation of antinatriuretic factors. At this later stage of disease, elevated levels of ANF are insufficient to counterbalance antinatriuretic influences. Thus the role of ANF in cirrhosis is primarily beneficial in that it successfully attenuates the antinatriuretic forces in the compensated stage. Raised ANF levels have two potential deleterious effects. First, ANF may exacerbate arterial vasodilation, leading to further sodium retention. The primacy of vasodilatation has been proposed as an alternate formulation to the overflow and underfill hypotheses. Second, Epstein et al. found higher basal ANF levels in cirrhotic patients with edema than in those patients without edema. ANF is known to reduce plasma volume in anephric animals and to increase the ultrafiltration coefficients of isolated capillaries. Therefore it is conceivable that in the clinical setting in which antinatriuretic factors limit the renal responsiveness to ANF but in which ANF levels are elevated (i.e., cirrhosis, congestive heart failure, primary kidney disease), ANF itself may contribute to edema formation at the level of the peripheral microcirculation. In general, ANF likely has no primary role in the sodium retention in cirrhosis. In early compensated cirrhosis, ANF may maintain sodium homeostasis despite the presence of mild antinatriuretic factors. In late ascitic cirrhosis renal resistance to ANF develops, rendering it ineffective.(ABSTRACT TRUNCATED AT 400 WORDS)
图4总结了心房钠尿肽(ANF)在肝硬化钠潴留中作用的有效表述。钠潴留始于肝硬化早期,这是肝静脉流出道阻塞或原发性血管舒张的结果。随之而来的血管内容量扩张导致ANF水平升高。在疾病的这个阶段,ANF水平的升高足以抵消利钠作用的影响。然而,这是以血管内容量扩张为代价的,存在腹水外溢的可能性。随着疾病进展,肝血窦内的Starling力遭到破坏,血管内的液体进入腹腔,导致血管内容量减少。循环血量的减少可能会减弱血浆ANF的进一步升高,并促进利钠因子的激活。在疾病的后期,升高的ANF水平不足以抵消利钠作用的影响。因此,ANF在肝硬化中的作用主要是有益的,因为它在代偿期成功地减弱了利钠作用。升高的ANF水平有两个潜在的有害作用。首先,ANF可能会加剧动脉血管舒张,导致进一步的钠潴留。血管舒张优先的观点被认为是对腹水外溢和循环血量减少假说的另一种解释。其次,爱泼斯坦等人发现,有水肿的肝硬化患者的基础ANF水平高于没有水肿的患者。已知ANF可减少无肾动物的血浆容量,并增加离体毛细血管的超滤系数。因此可以想象,在临床环境中,利钠因子会限制肾脏对ANF的反应,但ANF水平升高(即肝硬化、充血性心力衰竭、原发性肾病),ANF本身可能会在外周微循环水平上导致水肿形成。一般来说,ANF在肝硬化钠潴留中可能没有主要作用。在早期代偿性肝硬化中,尽管存在轻度利钠因子,ANF仍可能维持钠稳态。在晚期腹水型肝硬化中,肾脏对ANF产生抵抗,使其失效。(摘要截选至400词)